Browsing Tag
Genentech
31 posts
ATOMIC trial breakthrough: Atezolizumab + FOLFOX cuts colon cancer recurrence risk by 50%
Atezolizumab plus FOLFOX slashes recurrence risk in stage III dMMR colon cancer, says ATOMIC trial at ASCO 2025. Is this the new standard of care?
Roche bets big on America: $50bn to fuel next-gen weight loss drugs and diagnostics boom
Discover how Roche’s $50 billion U.S. investment is transforming pharma R&D, diagnostics, and job creation across eight states and reshaping global exports.
Recursion Pharmaceuticals’ stock plunges 7% after shock Q4 loss – What went wrong?
Recursion Pharmaceuticals, a clinical-stage biotechnology company leveraging artificial intelligence for drug discovery, reported a significantly wider loss for…
FDA approves Genentech’s Evrysdi tablet as first SMA treatment in tablet form
In a significant development for the treatment of spinal muscular atrophy (SMA), the U.S. Food and Drug Administration…
Roche’s Gazyva shows superior efficacy in lupus nephritis treatment, Phase III trial data reveals
Roche has announced promising new data from its phase III REGENCY clinical trial, published in the New England…
Cancer treatment just got faster: FDA approves Genentech’s Tecentriq Hybreza for quick 7-minute injection
The U.S. Food and Drug Administration (FDA) has granted approval for Tecentriq Hybreza, the first and only PD-(L)1…
Genentech announces reintroduction of Susvimo for Wet AMD treatment in US
Genentech, a key member of the Roche Group, has officially announced the reintroduction of Susvimo (ranibizumab injection) 100…
FDA approves Genentech’s Vabysmo prefilled syringe for eye diseases
In a significant advancement in the treatment of eye diseases, the U.S. Food and Drug Administration (FDA) has…
Lonza to acquire Genentech’s biologics manufacturing facility in Vacaville for $1.2bn
In a strategic move that significantly escalates its capacity in the biologics manufacturing landscape, Lonza, a key global…
FDA approves Genentech’s Xolair for food allergies: A new horizon in allergy treatment
The U.S. Food and Drug Administration (FDA) has approved Xolair (omalizumab) for reducing allergic reactions, including anaphylaxis, that…